ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 105 filers reported holding ALBIREO PHARMA INC in Q2 2022. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $659,105 | -73.2% | 30,500 | -76.0% | 0.00% | – |
| Q3 2022 | $2,461,000 | +24.5% | 127,125 | +27.6% | 0.00% | – |
| Q2 2022 | $1,977,000 | -58.5% | 99,594 | -37.6% | 0.00% | -100.0% |
| Q1 2022 | $4,761,000 | +28.2% | 159,616 | +0.1% | 0.00% | – |
| Q4 2021 | $3,714,000 | -43.0% | 159,496 | -23.7% | 0.00% | – |
| Q3 2021 | $6,518,000 | +7.1% | 208,922 | +20.8% | 0.00% | – |
| Q2 2021 | $6,086,000 | +45.4% | 172,998 | +45.7% | 0.00% | – |
| Q1 2021 | $4,185,000 | -40.3% | 118,727 | -36.5% | 0.00% | – |
| Q4 2020 | $7,008,000 | -65.1% | 186,846 | -69.0% | 0.00% | -100.0% |
| Q3 2020 | $20,091,000 | +766.7% | 602,072 | +587.9% | 0.00% | – |
| Q2 2020 | $2,318,000 | +211.1% | 87,517 | +92.3% | 0.00% | – |
| Q1 2020 | $745,000 | +153.4% | 45,500 | +209.5% | 0.00% | – |
| Q3 2019 | $294,000 | -7.0% | 14,700 | +50.0% | 0.00% | – |
| Q1 2019 | $316,000 | -69.1% | 9,800 | -68.8% | 0.00% | – |
| Q1 2018 | $1,023,000 | – | 31,415 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 480,000 | $14,318,000 | 9.25% |
| Decheng Capital Management III (Cayman), LLC | 518,342 | $15,462,000 | 4.74% |
| TANG CAPITAL MANAGEMENT LLC | 467,702 | $13,952,000 | 2.79% |
| Birchview Capital, LP | 113,000 | $3,371,000 | 2.43% |
| Privium Fund Management B.V. | 351,805 | $10,494,000 | 2.32% |
| Sio Capital Management, LLC | 144,546 | $4,312,000 | 1.43% |
| Perceptive Advisors | 2,360,139 | $70,403,000 | 1.41% |
| Chicago Capital, LLC | 1,011,744 | $30,180,000 | 1.30% |
| Endurant Capital Management LP | 120,834 | $3,604,000 | 0.95% |
| Nicholas Investment Partners, LP | 439,235 | $13,102,000 | 0.93% |